A cellular study suggests that CoQ10 can be cardioprotective without getting in the way of cancer treatment.
Researchers at Columbia University are exploring whether coenzyme Q10 (CoQ10) interferes with doxorubicin, a chemotherapy drug also known by the brand names Rubex and Adriamycin. Their recent in vitro study is now published in the journal Integrative Cancer Therapies.
Doxorubicin is used to treat a variety of cancers, including breast cancer, but it comes with the well-documented risk of congestive heart failure. If this health risk is due to an increased generation of reactive oxygen species in heart cell mitochondria, administering the antioxidant CoQ10 might counter that effect-a benefit so long as CoQ10 doesn’t also interfere with chemotherapy.
In a series of in vitro cell culture experiments, the researchers treated breast cancer cells with doxorubicin and various CoQ10 concentrations. Understandably, CoQ10 concentrations increased in the cells with high administration, but they also showed no interference with doxorubicin’s ability to slow cancer growth. The researchers confirmed this lack of an effect across a wide range of CoQ10 doses.
If CoQ10 can support the heart during chemotherapy, in vivo studies are warranted; so far, early signs in vivo are optimistic.
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.